10th Advances Against Aspergillosis and Mucormycosis

2 - 3 February 2022

Virtual Event

10th Advances Against Aspergillosis and Mucormycosis

2 - 3 February 2022

Virtual Event

10th Advances Against Aspergillosis and Mucormycosis

2 - 3 February 2022

Virtual Event

Programme

Because of challenging time zones and our desire to be as interactive as possible, we will pre-record talks and run them all, at different times on consecutive days, with different chairpersons to handle questions and discussion. Registration will allow access on both days to allow you to pick the most convenient times to join.

Go directly to a day’s programme
Wednesday | Thursday

Day 1: Wednesday 2nd February 2022

The timings below are in GMT. The link below will help you to work out the timings where you are:
https://greenwichmeantime.com/time-gadgets/time-zone-converter/

10.00Poster Session 1

Session 1: Novel Insights into the Pathogenesis of Aspergillosis

Moderators: David W. Denning, Manchester, UK & Elaine Bignell, Exeter, UK
11.00Introduction
David Denning, Manchester, UK
11.10Host responses to Aspergillus infection – why isn’t infection cleared?
Chad Steele, New Orleans, USA
11.30Sulphur metabolism as a promising source of new antifungal targets
Jorge Amich, Madrid, Spain
11.50Mechanistic basis of superinfection in influenza
Keven Mara Robinson, Pittsburgh, USA
12.10Selected abstract presentation: Aspergillus fumigatus pan-genome analysis identifies genetic variants associated with human infection
Amelia Barber, Jena, Germany
12.17Selected abstract presentation: Taking a closer look: Clinical and histopathological characteristics of culture-positive versus culture-negative pulmonary mucormycosis
Amy Spallone, Houston, USA
12.25Discussion
12.50
Break

Session 2: The Global Challenge of Chronic and Allergic Aspergillosis

Moderators: Adilia Warris, Exeter, UK & Tobias M. Hohl, New York, USA
13.15Sponsored by Journal of Fungi
Confusion between TB, NTM and sarcoidosis and chronic pulmonary aspergillosis or dual infection?

Felix Bongomin, Gulu, Uganda
13.35Keynote lecture supported by Pulmatrix
The clinical implications of Aspergillus sensitization in asthma

Luisa Brussino, Turin, Italy
13.55Clinical Aspergillus signatures in COPD and bronchiectasis
Sanjay Chotirmall, Singapore
14.15Selected abstract presentation: Mutual inhibition of antifungal and antiviral airway epithelial responses during fungal–viral coinfection
Sara Gago, Manchester, UK
14.22Selected abstract presentation: Characterisation of MAIT cells in the antifungal immune response in a microfluidic “invasive aspergillosis-on-chip” disease model
Susanne Jahreis, Jena, Germany
14.30Discussion
14.55Poster Session 2
15.55
Break

Session 3: COVID-19 Fungal Complications

Moderators: Dimitrios P. Kontoyiannis, Texas, USA & Ana Alastruey-Izquierdo, Madrid, Spain
16.15Debate: CAPA has been over-emphasised in the literature
For: Martin Hönigl, San Diego, USA and Graz, Austria (12 minutes)
Against: Michele Bartoletti, Bologna, Itay (12 minutes)
Debate (16 minutes)
16.55Developments in the diagnosis of mucormycosis
Eric Dannaoui, Paris, France
17.15Selected abstract presentation: Effect of iron on Aspergillus proteases: insight into possible therapeutic target for allergic bronchopulmonary aspergillosis
Paulami Chatterjee, Stanford, USA
17.22Selected abstract presentation: Diagnosis of COVID-19 associated pulmonary aspergillosis among mechanically ventilated COVID-19 patients using Galactomannan Lateral Flow Assay and culture
Mohammad T. Hedayati, Sari, Iran
17.30Discussion
17.55
Break

Session 4: Antifungal Resistance in Aspergillus – Not as Simple as First Thought

Moderators: Anuradha Chowdhary, Delhi, India & Paul E. Verweij, Nijmegen, The Netherlands
18.15Priming and tolerance – untold stories in understanding azole resistance in fumigatus
Nir Osherov, Tel Aviv, Israel
18.35Molecular epidemiological surprises in resistant Aspergilli
Matthew Fisher, London, UK
18.55The WHO Fungal Pathogen Priority list – implications for diagnosis, novel therapies and resistance surveillance
Hatim Sati, Geneva, Switzerland
19.15Selected abstract presentation: Stradam, a novel natural antifungal from the Canadian Arctic microbiome
Evelyne J. Côté, Montreal, Canada
19.22Discussion
19.45Close
19.50Poster Session 3
20.50
End of Day 1

Go directly to a day’s programme
Wednesday | Thursday

Day 2: Thursday 3rd February 2022

The timings below are in GMT. The link below will help you to work out the timings where you are:
https://greenwichmeantime.com/time-gadgets/time-zone-converter/

15.30Poster Session 4

Session 1: Novel Insights into the Pathogenesis of Aspergillosis

Moderators: William J. Steinbach, Arkansas, USA & Nancy Keller, Wisconsin, USA
17.00Introduction
David Denning, Manchester, UK
17.10Host responses to Aspergillus infection – why isn’t infection cleared?
Chad Steele, New Orleans, USA
17.30Sulphur metabolism as a promising source of new antifungal targets
Jorge Amich, Madrid, Spain
17.50Mechanistic basis of superinfection in influenza
Keven Mara Robinson, Pittsburgh, USA
18.10Selected abstract presentation: Aspergillus fumigatus pan-genome analysis identifies genetic variants associated with human infection
Amelia Barber, Jena, Germany
18.17Selected abstract presentation: Taking a closer look: Clinical and histopathological characteristics of culture-positive versus culture-negative pulmonary mucormycosis
Amy Spallone, Houston, USA
18.25Discussion
18.50
Break

Session 2: The Global Challenge of Chronic and Allergic Aspergillosis

Moderators: David A. Stevens, Stanford, USA & Ioly Kotta-Loizou, London, UK
19.15Sponsored by Journal of Fungi
Confusion between TB, NTM and sarcoidosis and chronic pulmonary aspergillosis or dual infection?

Felix Bongomin, Gulu, Uganda
19.35Keynote lecture supported by Pulmatrix
The clinical implications of Aspergillus sensitization in asthma

Luisa Brussino, Turin, Italy
19.55Clinical Aspergillus signatures in COPD and bronchiectasis
Sanjay Chotirmall, Singapore
20.15Selected abstract presentation: Mutual inhibition of antifungal and antiviral airway epithelial responses during fungal–viral coinfection
Sara Gago, Manchester, UK
20.22Selected abstract presentation: Characterisation of MAIT cells in the antifungal immune response in a microfluidic “invasive aspergillosis-on-chip” disease model
Susanne Jahreis, Jena, Germany
20.30Discussion
20.55Poster Session 5
21.55
Break

Session 3: COVID-19 Fungal Complications

Moderators: Monica Slavin, Melbourne, Australia & Martin Hönigl, Graz, Austria
22.15Debate: CAPA has been over-emphasised in the literature
For: Martin Hönigl, San Diego, USA and Graz, Austria (12 minutes)
Against: Michele Bartoletti, Bologna, Itay (12 minutes)
Debate (16 minutes)
22.55Developments in the diagnosis of mucormycosis
Eric Dannaoui, Paris, France
23.15Selected abstract presentation: Effect of iron on Aspergillus proteases: insight into possible therapeutic target for allergic bronchopulmonary aspergillosis
Paulami Chatterjee, Stanford, USA
23.22Selected abstract presentation: Diagnosis of COVID-19 associated pulmonary aspergillosis among mechanically ventilated COVID-19 patients using Galactomannan Lateral Flow Assay and culture
Mohammad T. Hedayati, Sari, Iran
23.30Discussion
23.55
Break

Session 4: Antifungal Resistance in Aspergillus – Not as Simple as First Thought

Moderators: Minh-Hong Nguyen, Pittsburgh, USA & Ashraf Ibrahim, Torrance, USA
00.15Priming and tolerance – untold stories in understanding azole resistance in fumigatus
Nir Osherov, Tel Aviv, Israel
00.35Molecular epidemiological surprises in resistant Aspergilli
Matthew Fisher, London, UK
00.55The WHO Fungal Pathogen Priority list – implications for diagnosis, novel therapies and resistance surveillance
Hatim Sati, Geneva, Switzerland
01.15Selected abstract presentation: Stradam, a novel natural antifungal from the Canadian Arctic microbiome
Evelyne J. Côté, Montreal, Canada
01.22Discussion
01.45Close
01.50Poster Session 6
02.50
End of Day 2

AAAM2022
AAAM2022
AAAM2022